LX103 eye treatment for X-linked retinoschisis
Part of Eyes & vision clinical trials.
This trial studies whether LX103 can improve vision and is safe for people with X-linked retinoschisis (XLRS) caused by RS1 gene changes. It focuses on a specific level of vision in the study eye and checks for medical conditions that could affect eye testing or safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your child) must agree to sign informed consent and come to follow-up visits
- You must be male, age 6 or older, with XLRS confirmed by RS1 gene mutation testing
- The study eye’s best corrected vision must be 63 letters or worse on the E-ETDRS chart
- The study eye must not have other eye problems that would make eye exam pictures hard to read
- Do not use (and not have used in the last 3 months) eye drops called topical carbonic anhydrase inhibitors in the study eye
- The study eye must not have had any eye surgery within the last 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests a gene therapy (ATSN-201) to improve or preserve vision in people with RS1-associated X-linked retinoschisis (XLRS), a genetic eye condition. You may qualify if you have a certain level of vision and specific eye “schisis” changes seen on a scan.
This trial tests a single gene therapy injection under the retina for boys with X-linked retinoschisis, a condition that causes vision loss. It aims to see if the treatment is safe and can improve vision.
This trial tests a gene therapy called LX107 for people with vision loss caused by changes in the AIPL1 gene. It aims to see if the treatment is safe and can improve vision.
This study tests a new gene therapy called LX111 for diabetic macular edema (DME) that has not improved enough with previous injections. It aims to see if a single treatment can reduce swelling and improve vision.
This trial tests a gene therapy injection (UGX202) for people with advanced retinitis pigmentosa (RP) who have very poor vision. It aims to see if the treatment can help improve or preserve sight.
This trial tests a new gene therapy (LX111) for people with wet age-related macular degeneration (AMD) who have already been helped by standard anti-VEGF injections. The goal is to see if one dose of LX111 can reduce the need for frequent eye injections.
Hear when a new X-linked Retinoschisis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.